PUBLISHER: TechNavio | PRODUCT CODE: 2126170
PUBLISHER: TechNavio | PRODUCT CODE: 2126170
Global RNA Based Therapeutics Market 2026-2030
The global RNA based therapeutics market is forecasted to grow by USD 1420.7 mn during 2025-2030, accelerating at a CAGR of 5.6% during the forecast period. The report on the global RNA based therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expansion of clinical pipeline applications, industrial-scale manufacturing drives genetic medicine growth, precision medicine accelerates rna therapeutics adoption.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 5.4% |
| CAGR | 5.6% |
| Incremental Value | $1420.7 mn |
Technavio's global RNA based therapeutics market is segmented as below:
By Type
- mRNA therapeutics
- Antisense oligonucleotide (ASO) therapeutics
- RNA interference (RNAi) therapeutics
- Others
By Route Of Administration
- Intravenous (IV)
- Subcutaneous (SC)
- Intramuscular (IM)
By Application
- Oncology
- Infectious diseases
- Genetic disorders
- Others
By Product Type
- Vaccines
- Drugs
Geography
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- North America
- US
- Canada
- Mexico
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the rapid expansion of clinical pipelines as one of the prime reasons driving the global rna based therapeutics market growth during the next few years. Also, strategic collaborations and licensing agreements and advancements in delivery system technologies will lead to sizable demand in the market.
The report on the global rna based therapeutics market covers the following areas:
- Global rna based therapeutics market sizing
- Global rna based therapeutics market forecast
- Global rna based therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global rna based therapeutics market vendors that include Abogen Biosciences, Alnylam Pharmaceuticals Inc., Arcturus Therapeutics Holdings, Arrowhead Pharmaceuticals Inc., Avidity Biosciences Inc., BioNTech SE, Eli Lilly and Co., Ionis Pharmaceuticals Inc., Moderna Inc., Novartis AG, ProQR Therapeutics, ReCode Therapeutics, Sail Biomedicines Inc., Sarepta Therapeutics Inc., ShapeTX, Stoke Therapeutics Inc., Strand Therapeutics Inc., Wave Life Sciences Ltd.. Also, the global rna based therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Product Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global RNA Based Therapeutics Market 2020 - 2024
- Historic Market Size - Data Table on Global RNA Based Therapeutics Market 2020 - 2024 ($ million)
- 5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- 5.3 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.4 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
- 5.5 Product Type segment analysis 2020 - 2024
- Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
- 5.6 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.7 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global RNA Based Therapeutics Market
- 6.2 Impact of geopolitical conflicts on Global RNA Based Therapeutics Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Type
- 8.1 Market segments
- 8.2 Comparison by Type
- 8.3 mRNA therapeutics - Market size and forecast 2025-2030
- 8.4 Antisense oligonucleotide (ASO) therapeutics - Market size and forecast 2025-2030
- 8.5 RNA interference (RNAi) therapeutics - Market size and forecast 2025-2030
- 8.6 Others - Market size and forecast 2025-2030
- 8.7 Market opportunity by Type
- Market opportunity by Type ($ million)
9 Market Segmentation by Route of Administration
- 9.1 Market segments
- 9.2 Comparison by Route of Administration
- 9.3 Intravenous (IV) - Market size and forecast 2025-2030
- 9.4 Subcutaneous (SC) - Market size and forecast 2025-2030
- 9.5 Intramuscular (IM) - Market size and forecast 2025-2030
- 9.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
10 Market Segmentation by Application
- 10.1 Market segments
- 10.2 Comparison by Application
- 10.3 Oncology - Market size and forecast 2025-2030
- 10.4 Infectious diseases - Market size and forecast 2025-2030
- 10.5 Genetic disorders - Market size and forecast 2025-2030
- 10.6 Others - Market size and forecast 2025-2030
- 10.7 Market opportunity by Application
- Market opportunity by Application ($ million)
11 Market Segmentation by Product Type
- 11.1 Market segments
- 11.2 Comparison by Product Type
- 11.3 Vaccines - Market size and forecast 2025-2030
- 11.4 Drugs - Market size and forecast 2025-2030
- 11.5 Market opportunity by Product Type
- Market opportunity by Product Type ($ million)
12 Customer Landscape
- 12.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
13 Geographic Landscape
- 13.1 Geographic segmentation
- 13.2 Geographic comparison
- 13.3 Europe - Market size and forecast 2025-2030
- 13.3.1 Germany - Market size and forecast 2025-2030
- 13.3.2 UK - Market size and forecast 2025-2030
- 13.3.3 France - Market size and forecast 2025-2030
- 13.3.4 Italy - Market size and forecast 2025-2030
- 13.3.5 Spain - Market size and forecast 2025-2030
- 13.3.6 The Netherlands - Market size and forecast 2025-2030
- 13.4 North America - Market size and forecast 2025-2030
- 13.4.1 US - Market size and forecast 2025-2030
- 13.4.2 Canada - Market size and forecast 2025-2030
- 13.4.3 Mexico - Market size and forecast 2025-2030
- 13.5 Asia - Market size and forecast 2025-2030
- 13.5.1 China - Market size and forecast 2025-2030
- 13.5.2 Japan - Market size and forecast 2025-2030
- 13.5.3 India - Market size and forecast 2025-2030
- 13.5.4 South Korea - Market size and forecast 2025-2030
- 13.5.5 Singapore - Market size and forecast 2025-2030
- 13.5.6 Taiwan - Market size and forecast 2025-2030
- 13.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 13.6.1 Brazil - Market size and forecast 2025-2030
- 13.6.2 Australia - Market size and forecast 2025-2030
- 13.6.3 Israel - Market size and forecast 2025-2030
- 13.6.4 Saudi Arabia - Market size and forecast 2025-2030
- 13.6.5 UAE - Market size and forecast 2025-2030
- 13.6.6 South Africa - Market size and forecast 2025-2030
- 13.6.7 Argentina - Market size and forecast 2025-2030
- 13.6.8 Turkey - Market size and forecast 2025-2030
- 13.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
14 Drivers, Challenges, and Opportunity
- 14.1 Market drivers
- Expansion of clinical pipeline applications
- Industrial-scale manufacturing drives genetic medicine growth
- Precision medicine accelerates RNA therapeutics adoption
- 14.2 Market challenges
- Complex delivery systems and extrahepatic barriers
- Stringent and fragmented regulatory frameworks
- Exorbitant cold chain infrastructure expenses
- 14.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 14.4 Market opportunities
- Rapid expansion of clinical pipelines
- Strategic collaborations and licensing agreements
- Advancements in delivery system technologies
15 Competitive Landscape
- 15.1 Overview
- 15.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 15.3 Landscape disruption
- Overview on factors of disruption
- 15.4 Industry risks
- Impact of key risks on business
16 Competitive Analysis
- 16.1 Companies profiled
- Companies covered
- 16.2 Company ranking index
- Company ranking index
- 16.3 Market positioning of companies
- Matrix on companies position and classification
- 16.4 Abogen Biosciences
- Abogen Biosciences - Overview
- Abogen Biosciences - Product / Service
- Abogen Biosciences - Key offerings
- SWOT
- 16.5 Alnylam Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc. - Overview
- Alnylam Pharmaceuticals Inc. - Product / Service
- Alnylam Pharmaceuticals Inc. - Key offerings
- SWOT
- 16.6 Arcturus Therapeutics Holdings
- Arcturus Therapeutics Holdings - Overview
- Arcturus Therapeutics Holdings - Product / Service
- Arcturus Therapeutics Holdings - Key offerings
- SWOT
- 16.7 Avidity Biosciences Inc.
- Avidity Biosciences Inc. - Overview
- Avidity Biosciences Inc. - Product / Service
- Avidity Biosciences Inc. - Key offerings
- SWOT
- 16.8 BioNTech SE
- BioNTech SE - Overview
- BioNTech SE - Product / Service
- BioNTech SE - Key offerings
- SWOT
- 16.9 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key news
- Eli Lilly and Co. - Key offerings
- SWOT
- 16.10 Ionis Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc. - Overview
- Ionis Pharmaceuticals Inc. - Product / Service
- Ionis Pharmaceuticals Inc. - Key offerings
- SWOT
- 16.11 Moderna Inc.
- Moderna Inc. - Overview
- Moderna Inc. - Product / Service
- Moderna Inc. - Key offerings
- SWOT
- 16.12 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 16.13 ProQR Therapeutics
- ProQR Therapeutics - Overview
- ProQR Therapeutics - Product / Service
- ProQR Therapeutics - Key offerings
- SWOT
- 16.14 Sail Biomedicines Inc.
- Sail Biomedicines Inc. - Overview
- Sail Biomedicines Inc. - Product / Service
- Sail Biomedicines Inc. - Key offerings
- SWOT
- 16.15 Sarepta Therapeutics Inc.
- Sarepta Therapeutics Inc. - Overview
- Sarepta Therapeutics Inc. - Product / Service
- Sarepta Therapeutics Inc. - Key offerings
- SWOT
- 16.16 ShapeTX
- ShapeTX - Overview
- ShapeTX - Product / Service
- ShapeTX - Key offerings
- SWOT
- 16.17 Stoke Therapeutics Inc.
- Stoke Therapeutics Inc. - Overview
- Stoke Therapeutics Inc. - Product / Service
- Stoke Therapeutics Inc. - Key offerings
- SWOT
- 16.18 Wave Life Sciences Ltd.
- Wave Life Sciences Ltd. - Overview
- Wave Life Sciences Ltd. - Product / Service
- Wave Life Sciences Ltd. - Key offerings
- SWOT
17 Appendix
- 17.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 17.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 17.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 17.4 Research methodology
- Research methodology
- 17.5 Data procurement
- Information sources
- 17.6 Data validation
- Data validation
- 17.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 17.8 Data synthesis
- Data synthesis
- 17.9 360 degree market analysis
- 360 degree market analysis
- 17.10 List of abbreviations
- List of abbreviations
